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Lung cancer is the leading cause of cancer deaths
worldwide; approximately 85% of these cancers are
non-small cell lung cancer (NSCLC). Patients with
NSCLC frequently have tumors harboring somatic mu-
tations in the epidermal growth factor receptor
(EGFR) gene that cause constitutive receptor activa-
tion. These patients have the best clinical response to
EGFR tyrosine kinase inhibitors (TKIs). Herein, we
show that fibroblast growth factor–inducible 14
(Fn14; TNFRSF12A) is frequently overexpressed in
NSCLC tumors, and Fn14 levels correlate with p-EGFR
expression. We also report that NSCLC cell lines that
contain EGFR-activating mutations show high levels
of Fn14 protein expression. EGFR TKI treatment of
EGFR-mutant HCC827 cells decreased Fn14 protein
levels, whereas EGF stimulation of EGFR wild-type
A549 cells transiently increased Fn14 expression. Fur-
thermore, Fn14 is highly expressed in EGFR-mutant
H1975 cells that also contain an EGFR TKI-resistance
mutation, and high TKI doses are necessary to reduce
Fn14 levels. Constructs encoding EGFRs with activat-
ing mutations induced Fn14 expression when ex-pressed in rat lung epithelial cells. We also report that
short hairpin RNA–mediated Fn14 knockdown re-
duced NSCLC cell migration and invasion in vitro.
Finally, Fn14 overexpression enhanced NSCLC cell
migration and invasion in vitro and increased exper-
imental lung metastases in vivo. Thus, Fn14 may be a
novel therapeutic target for patients with NSCLC, in
particular for those with EGFR-driven tumors who
have either primary or acquired resistance to EGFR
TKIs. (Am J Pathol 2012, 181:111–120; http://dx.doi.org/
10.1016/j.ajpath.2012.03.026)
Lung cancer is the leading cause of cancer deaths
worldwide. In the United States alone, there were
222,520 new cases and 157,300 deaths in 2010.1 Of
lung cancers, 85% are classified as non-small cell lung
cancer (NSCLC), which is further divided into adeno-
carcinoma, squamous cell carcinoma, and large-cell
carcinoma. More recently, molecular subsets of ade-
nocarcinomas have been identified, with specific
genomic alterations initiating and maintaining the ma-
lignancy. One such genomic alteration is the overex-
pression and/or mutation of the epidermal growth fac-
tor receptor (EGFR).
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AJP July 2012, Vol. 181, No. 1EGFR is overexpressed in 40% to 80% of patients with
NSCLC and is correlated with disease progression and
overall poor survival.2,3 Thus, EGFR tyrosine kinase in-
hibitors (TKIs), such as gefitinib and erlotinib, became
promising therapies for patients with NSCLC. The clinical
response rates for these drugs were unexpectedly low
(10% as single agents) and prompted investigation into
patient subgroups that might benefit from EGFR-targeted
drugs.4–6 Two seminal studies described mutations in
the EGFR gene that correlated to clinical response to
gefitinib.7,8 Patients with EGFR mutations were more sen-
sitive to gefitinib and showed improved progression-free
survival. Approximately 10% to 15% of the patients with
NSCLC in the Western hemisphere and 30% to 50% of
patients of Asian ethnicity have tumors harboring somatic
mutations in the EGFR that cause constitutive activation
of this receptor.6,9 Despite the success of TKIs in patients
with lung tumors harboring EGFR-activating mutations,
many patients develop resistance to gefitinib and erlo-
tinib and show disease progression. Mechanisms of ac-
quired resistance to EGFR TKI therapy, such as the sec-
ondary mutation in exon 20 (T790M),10 or amplification of
other growth factor receptors, such as c-Met,11–13 have
been described. In addition, K-ras mutations, which oc-
cur in 15% to 20% of NSCLCs,14 have been described as
a resistance mechanism to EGFR-directed therapy in
NSCLC and colon cancer.15 Thus, the molecular mech-
anisms that govern the progression of these lung tumors
with EGFR mutations and resistance to anti-EGFR thera-
pies remain to be elucidated.
Fibroblast growth factor–inducible 14 (Fn14; gene
TNFRSF12A) is the smallest known member of the tumor
necrosis factor superfamily of receptors, and its only
known ligand is the multifunctional cytokine tumor necro-
sis factor–like weak inducer of apoptosis (TWEAK).16 The
TWEAK/Fn14 signaling axis has been implicated in
tumor growth and metastasis. Increased expression of
Fn14 has been observed in several solid tumors, in-
cluding hepatocellular carcinoma,17 glioblastoma,18,19
esophageal adenocarcinoma,20,21 and HER2 breast
cancer.22,23 In glioblastoma, Fn14 signaling modulates
cell survival through regulation of NF-B, Bcl-XL, Bcl-2
expression, and Akt2 activation.24,25 Fn14 signaling also
promotes glioma and breast cell invasion through activa-
tion of Rac1 and NF-B.19,22 Fn14 expression has been
detected in NSCLC specimens,26 but little is known about
the role of Fn14 in this tumor type.
In this study, we show that Fn14 is frequently highly
expressed in NSCLCs and that, in NSCLC cell lines, Fn14
expression often occurs concurrently with activating
EGFR mutations. We further show that Fn14 expression is
induced by EGF and repressed by erlotinib, implicating
the importance of EGFR signaling in regulating Fn14 ex-
pression. In an NSCLC cell line that is resistant to erlotinib
because of an EGFR T790M mutation, Fn14 expression
remains elevated unless a relatively high EGFR TKI dose
is used. We also demonstrate that the expression of
Fn14 modulates cell migration and invasion in NSCLC
cells in vitro and that ectopic expression of Fn14 aug-
ments NSCLC tumor formation in an experimental me-
tastasis assay. Together, these data suggest that Fn14signaling contributes to NSCLC cell motility and inva-
sion and that Fn14 may be a new potential target for
NSCLC treatment.
Materials and Methods
Tumor TMA
Lung cancer samples were obtained from patients who
underwent total tumor resection. Specimen blocks cho-
sen for the TMA met the criteria of nonnecrotic, nonirra-
diated, or chemo-treated lung cancer tissue. NSCLC
subtypes included adenocarcinoma (n  179) and squa-
mous cell carcinoma (n  111). Samples were double
punched (0.6 m diameter) using an indexed manual
arrayer with an attached stereomicroscope under the
direction of one of the authors (G.H.), who also reviewed
and verified the tumor content. IHC analysis for Fn14 was
performed using the Fn14 monoclonal antibody P4A8
(Biogen Idec, Inc., Weston, MA), as previously de-
scribed.19 p-EGFR analysis was performed using an an-
tibody specific for EGFR-Y1068 (Cell Signaling Technol-
ogies, Beverly, CA). A scoring system for each
chromophore, composed of staining intensity and exten-
siveness, captured the outcome: 0, negative; 1, weak; 2
moderate; and 3, strong.
Cell Culture
Human NSCLC cell lines H520, H2122, A549, H1703,
H358, H3255, H1975, HCC2279, and HCC827 (ATCC,
Manassas, VA) were maintained in RPMI 1640 medium
(Invitrogen, Carlsbad, CA), supplemented with 10% heat-
inactivated fetal bovine serum (FBS) in a 37°C, 5% CO2
atmosphere. For the EGF stimulation and erlotinib treat-
ment experiments, cells were placed in RPMI 1640 me-
dium supplemented with 0.5% FBS for 18 hours before
growth factor or drug addition.
Reagents, Antibodies, and Immunoblot Analysis
Erlotinib was obtained from BioVision (Mountain View,
CA). EGF was obtained from Millipore (Billerica, MA) or
R&D Systems (Minneapolis, MN). Polyclonal Fn14 anti-
bodies were either generated by us27 or obtained from
Cell Signaling Technologies. Antibodies specific to p-
EGFR (Y-1068), total EGFR, EGFR L858R mutant, and the
EGFR E746-A750 deletion mutant were obtained from
Cell Signaling Technologies. The -tubulin antibody was
obtained from Millipore or eBioscience (San Diego, CA),
and the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and hemagglutinin epitope antibodies were ob-
tained from Cell Signaling Technologies. Immunoblot
analysis was performed as previously described.25
Expression of EGFR Variants and K-ras V12 in
Immortalized Rat Bronchiolar Epithelial Cells
The rat bronchiolar epithelial cell line RL-65 (ATCC) was
grown and maintained as previously described.28 The
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11011) and EGFR mutants (L858R-11012, L747-E749
del-11015, D770-N771 ins-11016, and D837-11014)
were obtained from Addgene (Cambridge, MA) and were
previously described.29 The K-ras V12 pBABE construct
(9052) and the empty pBABE vector (1764) were also
obtained from Addgene.org. Replication-incompetent
retroviruses were produced from the EGFR constructs by
transfection into the Phoenix 293T packaging cell line
(Allele Biotech, San Diego, CA) using Lipofectamine
2000 (Invitrogen). RL-65 cells were infected with these
retroviruses in the presence of 5 g/mL polybrene. At 24
hours after infection, 2 g/mL puromycin was added to me-
dia, and cells were maintained for 5 days before lysis and
immunoblotting for Fn14, p-EGFR, EGFR, and GAPDH.
Lentiviral Constructs and Transduction
Lentiviral constructs (pGIPZ) containing nonsilencing
short hairpin RNA (shRNA) or shRNAs targeting two dif-
ferent regions of the Fn14 transcript (Fn14shRNA154,
clone ID V3LHS_380154; Fn14shRNA156, clone ID
V3LHS_380156) were obtained from Open Biosystems
(Huntsville, AL). To generate the Fn14 overexpression
construct, the coding sequence for Fn14 was amplified
by PCR and ligated in-frame upstream of a 3XHA epitope
in pcDNA3. For stable transduction, the HA epitope–
tagged Fn14 fragment was excised from pcDNA3 and
ligated into the lentiviral transfer vector pCDH (System
Biosciences, Mountain View, CA) that contains a second
transcriptional cassette for the expression of green fluo-
rescent protein (GFP). An empty pCDH vector expressing
only GFP or a nonsilencing shRNAmir vector expressing
GFP was used as a control in an overexpression or knock-
down experiment, respectively. Vesicular stomatitis virus-G-
pseudotyped recombinant lentiviruses encoding Fn14 were
produced by cotransfection of 293 packaging cells with the
pCDH-Fn14 HA construct and the pPACK packaging mix
(System Biosciences), according to the manufacturer’s di-
rections. Pseudotyped lentiviruses encoding shRNAs were
produced by cotransfection of packaging cells with the
appropriate shRNA construct and the Trans-Lentiviral Pack-
aging Extract (Open Biosystems), according to the manu-
facturer’s protocol. For lentiviral transduction, medium con-
taining recombinant lentiviruses was harvested from the
packaging cells at 48 hours after transfection, concentrated
by polyethylene glycol precipitation and centrifugation, and
added to subconfluent cultures of cells together with 8
g/mL polybrene. Positively transduced cells were en-
riched by mass sorting the GFP-positive cells on a Vantage
flow cytometer (BD Biosciences, San Jose, CA).
Migration and Invasion
Migration was assessed using a 25  80-mm polycarbon-
ate membrane (8 mol/L pore) and 12-well Chemotaxis
Chamber (Neuro Probe Inc., Gaithersburg, MD). Cells (5 
104) were seeded into each of 12 wells and allowed to
migrate through the membrane for 5 hours. Cells were
maintained in RPMI 1640 medium (Invitrogen) without FBS
throughout the experiment. For EGF-induced migration,
EGF (50 ng/mL) was placed in the bottom chamber. Alltreatments were performed in triplicate. Stationary cells
were removed from the top of the membrane by scraping,
and the membrane was fixed in 70% methanol. The mem-
brane was stained with DAPI and mounted on a glass slide.
Cells were counted from five random fields using fluores-
cent microscopy.
For the invasion assays, 1  105 cells suspended in
RPMI 1640 medium with 0.5% serum were seeded into
growth factor–reduced Matrigel invasion chambers (BD
Biosciences). Chambers were placed in a 24-well plate
containing RPMI 1640 medium and 10% FBS. Cells were
allowed to invade through the membrane for 20 hours.
For EGF-induced invasion, the bottom chamber con-
tained RPMI 1640 medium with 0.5% serum and 50
ng/mL EGF. All treatments were performed in triplicate.
Cells were fixed and stained in 0.1% crystal violet in 20%
methanol. Stationary cells were removed from the top of
the membrane by scraping, and the membrane was
mounted on a glass slide. Cells were counted from six
random fields using light microscopy.
Tail Vein Injection of A549 Cells
A549 lung adenocarcinoma cells (5  105) stably infected
with either lentiviral vector or human Fn14 with an HA
epitope tag (hFn14-HA) lentivirus (n  9 per group) were
injected i.v. (tail vein) into beige mice with severe combined
immunodeficiency (Taconic, Hudson, NY), as previously
described.30 Six weeks after injection, mice were sacrificed
and lungs were fixed in 10% neutral-buffered formalin.
Lungs were evaluated for metastatic surface nodules by
gross visualization. Tumor lesions were counted in a
blinded manner using a dissecting microscope. Tissue was
then embedded in paraffin and divided into sections (4 m
thick). Sections were stained with H&E using standard pro-
cedures, and immunohistochemical (IHC) staining was per-
formed using an anti-HA antibody (Cell Signaling Technol-
ogies).
Statistics
For TMA, tests for correlation using the rank-based Ken-
dall’s  statistic were calculated using the cor. test func-
tion in the R statistical package (http://www.r-project.org,
last accessed February 11, 2011). Migration and invasion
assay results were assessed using the two-sample Stu-
dent’s t-test. P  0.05 was considered significant.
Results
Fn14 Is Overexpressed in Primary Human
NSCLC Tumors, and High Fn14 Levels
Correlate with EGFR Phosphorylation
We examined, by IHC staining of a lung TMA, whether
Fn14 was expressed in primary human NSCLC tumors
and, if so, whether those tumors with elevated Fn14 ex-
pression had activated EGFR, as assessed by staining
with a p-EGFR (Y-1068) antibody. Representative staining
patterns of an Fn14-negative/p-EGFR–negative patient and
ution of
two sta
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ure 1A. Fn14 showed moderate to strong staining (scores 2
and 3) in 48.6% of adenocarcinoma specimens and 31.5%
of squamous cell carcinoma specimens (Figure 1B). To
determine whether Fn14 protein staining correlated with
activated EGFR expression, tumors were scored for both
Fn14 and p-EGFR protein staining. There was a statistically
significant positive correlation (P 0.01) between Fn14 and
p-EGFR expression in both adenocarcinoma and squa-
mous cell carcinoma subtypes, as determined by the Ken-
Figure 1. Fn14 expression in human NSCLC specimens and correlation with EG
patients with lung adenocarcinoma (5 objective, Aperio GL Scanner; Aperio, V
of the tumor punches was scored by a board-certified pathologist; a score of 0 ind
staining (1, minimum; 2, moderate; 3, strong positive). B: The percentage distrib
were scored for Fn14 and p-EGFR expression, and the correlation between thedall’s  rank correlation test (Figure 1C).Fn14 Is Highly Expressed in EGFR- or
K-ras–Mutated NSCLC Cell Lines
We assessed the protein expression of Fn14 across nine
NSCLC cell lines by immunoblot analysis. Fn14 expression
was detected in five of six cell lines classified as adenocar-
cinoma, and in an adenocarcinoma in situ cell line, but
expression was much lower in the two squamous cell car-
cinoma cell lines (Figure 2). Relatively high levels of Fn14
often coincided with p-EGFR expression (Y-1068), driven
sphorylation. A: Fn14 and p-EGFR staining on representative samples from two
). Insets: 40 objective. Tumor cell–specific Fn14 and p-EGFR staining in each
staining level equal to adjacent nontumor cells. A non-0 score indicates increased
staining intensity of Fn14 in NSCLC patient specimens. C: A total of 290 samples
ins was analyzed using Kendall’s  rank correlation test.FR pho
ista, CA
icates aby activating EGFR mutations (L858R and E746-A750),
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ondary mutation (T790M) known to confer resistance to
EGFR TKIs. In addition, Fn14 protein was also highly ex-
pressed in two of the three cell lines (A549 and H358) with
activating K-ras mutations.
Erlotinib Suppresses Fn14 Expression
To assess whether constitutive EGFR signaling was di-
rectly triggering Fn14 expression, we used the small-
molecule EGFR kinase inhibitor, erlotinib. Treatment of
HCC827 cells with 1 mol/L erlotinib inhibited EGFR
activation, as detected by decreased p-EGFR protein
expression (Figure 3A). In addition, erlotinib treatment
decreased the level of Fn14 protein expression in a time-
dependent (Figure 3A) and dose-dependent (Figure 3B)
manner. Erlotinib treatment also decreased Fn14 expres-
sion in two other cell lines with activating EGFR muta-
tions: H3255 and HCC2279 (data not shown). Treatment
of the H1975 NSCLC cell line, which contains both an
EGFR-activating mutation and an EGFR-TKI resistance
mutation, required a 1000-fold higher erlotinib dose to
decrease p-EGFR and Fn14 levels compared with
HCC827 cells (Figure 3B).
Activating EGFR Mutations Increase Fn14
Expression in Lung Epithelial Cells
To further investigate the relationship between acti-
vated EGFR and Fn14 expression, we expressed both
activating and nonactivating EGFR constructs in a non-
Figure 2. Fn14 expression levels in various NSCLC cell lines. Total cell
lysates were prepared from various NSCLC cell lines [squamous cell carci-
noma (SCC), adenocarcinoma (AC), and adenocarcinoma in situ (AIS)] and
immunoblotted with the indicated antibodies: Fn14, p-EGFR (Y-1068), EGFR,
EGFR L858R mutant, or EGFR E746-A750 deletion mutant. Tubulin was used
as a loading control. MT, mutant; WT, wild type.transformed, immortalized rat lung epithelial cell line
(RL-65). Expression of wild-type EGFR and mutant
EGFR receptors increased p-EGFR levels compared
with vector control or mutant K-ras retrovirus-infected
cells (Figure 4). It is likely that phosphorylation of the
kinase-dead EGFR mutant (D837A) occurred either via
Figure 3. Erlotinib treatment of TKI-sensitive NSCLC cells decreases Fn14
expression. A: Serum-starved HCC827 cells containing the EGFR E746-A750–
activating mutation were treated with vehicle for 12 hours or 1 mol/L
erlotinib for the indicated time periods. Cells were harvested, and total cell
lysates were prepared and immunoblotted with the indicated antibodies to
Fn14, p-EGFR, or total EGFR. Tubulin was used as a loading control. B:
HCC827 cells containing the EGFR E746-A750–activating mutation and
H1975 cells containing the EGFR L858R-activating mutation and the EGFR
T790M drug-resistance mutation were serum starved and then treated with
vehicle or the indicated concentration of erlotinib for 8 hours. Immunoblot-
ting was conducted as described for A.
Figure 4. Ectopic expression of wild-type (WT) EGFR, activated EGFR mu-
tants, and the K-rasV12 mutant in rat lung epithelial cells (RL-65) induces Fn14
expression. Total cellular lysates from RL-65 cells stably expressing the
indicated EGFR receptors or K-rasV12 were prepared and analyzed by immu-
noblotting for Fn14, p-EGFR, and total EGFR. GAPDH was used as a loading
control.
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activity of other tyrosine kinases in the RL-65 cells.
Fn14 protein expression was induced in both the wild-
type and activating EGFR mutation cells; in contrast,
expression of the kinase-dead EGFR mutant failed to
enhance Fn14 expression. Notably, expression of a
K-ras mutant (V12) in RL-65 cells also resulted in in-
creased Fn14 expression.
Fn14 Depletion Reduces NSCLC Cell Migration
and Invasive Capacity in Vitro
We next investigated whether depletion of Fn14 expres-
sion by shRNA could suppress NSCLC cell migration and
invasion. Cells stably expressing Fn14 shRNA 154 or
156, targeting the Fn14 transcript, showed a suppression
of Fn14 levels in both HCC827 (Figure 5A) and H1975
(Figure 5B) cells. These cell lines were less migratory and
Figure 5. Depletion of Fn14 expression by shRNA reduces NSCLC cell
migration and invasion. A: HCC827 cells were infected with lentiviruses
expressing two different Fn14 shRNAs or control nontargeting shRNA. Stable
cell lines were isolated, cell lysates were prepared, and immunoblotting was
conducted using the indicated antibodies to Fn14 or tubulin (loading con-
trol). B: H1975 cells were infected with lentivirus expressing the most effec-
tive Fn14 shRNA or control nontargeting shRNA. Stable cell lines were
isolated, cell lysates were prepared, and immunoblotting was conducted
using antibodies to Fn14 or GAPDH (loading control). C: Transwell migration
assay of HCC827 cell lines expressing control shRNA or Fn14 shRNAs. D:
Transwell migration assay of H1975 cell lines expressing control shRNA or
Fn14 shRNA. E: Matrigel invasion assay of HCC827 cell lines expressing
control shRNA or Fn14 shRNAs. F: Matrigel invasion assay of H1975 cell lines
expressing control shRNA or Fn14 shRNA. For migration and invasion assays,
the values shown are the mean  SEM of triplicate chambers. Significance
was assessed by the Student’s t-test. *P  0.05, **P  0.01.invasive compared with control cells. Specifically, the
knockdown of Fn14 by shRNA suppressed NSCLC cell
migration by 64% (shRNA 154) or 81% (shRNA 156) in
HCC827 cells and 50% (shRNA 156) in H1975 cells (Fig-
ure 5, C and D). The depletion of Fn14 by shRNA sup-
pressed cell invasion by 50% (shRNA 154) or 66%
(shRNA 156) in HCC827 cells and 37% (shRNA 156) in
H1975 cells (Figure 5, E and F).
Fn14 Depletion Attenuates EGF-Induced
NSCLC Cell Migration and Invasion in Vitro
Because Fn14 expression was modulated by EGFR sig-
naling, and Fn14 influenced baseline NSCLC cell migra-
tion and invasion, we tested whether Fn14 depletion also
reduced EGF-driven cell migration and invasion. We
found that EGF treatment of A549 cells increased Fn14
protein expression, with maximal induction at 4 hours
Figure 6. Depletion of Fn14 reduces EGF-stimulated NSCLC cell migration
and invasion. A: Serum-starved A549 cells were treated with 50 ng/mL EGF
for the indicated times. Cells were harvested, and total cell lysates were
prepared and immunoblotted with an antibody against Fn14. GAPDH was
used as a loading control. B: A549 cells were infected with lentivirus ex-
pressing an Fn14 shRNA (156) or control nontargeting shRNA. Stable cell
lines were isolated, cell lysates were prepared, and immunoblotting was
conducted using the indicated antibodies against Fn14 and GAPDH (loading
control). C: Transwell migration assay of A549 cells expressing control or
Fn14 shRNA and either left untreated or treated with 50 ng/mL EGF. D:
Matrigel invasion assay of A549 cells expressing control or Fn14 shRNA and
either left untreated or treated with 50 ng/mL EGF. For migration and
invasion assays, the values shown are the mean  SEM of triplicate cham-
bers. Significance was assessed by the Student’s t-test. **P  0.01.(Figure 6A). Next, we generated an Fn14-deficient A549
SEM of triplicate chambers. Significance was assessed by the Student’s t-test. **P 
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with the shRNA 156 virus expressed low levels of Fn14
(Figure 6B). Although EGF treatment enhanced A549-con-
trol shRNA cell migration by approximately threefold, EGF
treatment of the A549 Fn14 shRNA cells increased migra-
tion by only approximately twofold (Figure 6C). Similarly,
EGF treatment also increased A549-control shRNA cell in-
vasion by approximately 10-fold, whereas the knockdown of
Fn14 suppressed EGF-driven cell invasion by 30% com-
pared with A549-control shRNA cells (Figure 6D).
Fn14 Overexpression Enhances NSCLC Cell
Motility and Invasion in Vitro
We next investigated whether Fn14 overexpression would
modulate NSCLC cell motility and invasion. We infected
A549 cells with control lentivirus or lentivirus encoding full-
length, hFn14-HA, and stable cell lines were isolated.
Fn14-HA expression in the A549 cell line was confirmed by
immunoblotting (Figure 7A). Compared with the vector-in-
fected A549 cells (control), ectopic expression of Fn14 en-
hanced cell migration approximately twofold (Figure 7B).
The expression of Fn14 also enhanced A549 cell invasion
by approximately 1.6-fold (Figure 7C).
Fn14 Overexpression Enhances Experimental
Metastasis in Vivo
Because our in vitro data indicated involvement of Fn14 in
migration and invasion of NSCLC cells, we next tested
whether overexpression of Fn14 could enhance NSCLC
tumor formation in an in vivo model of experimental me-
tastasis. Control or hFn14-HA–overexpressing A549 cells
were injected into the tail vein of Beige mice with severe
combined immunodeficiency. Mice were evaluated
grossly for lung tumors 6 weeks after injection. H&E stain-
ing of formalin-fixed, paraffin-embedded sections con-
firmed the presence of lung tumors (Figure 8A). The
Figure 7. Fn14 overexpression enhances NSCLC cell migration and invasion
or vector alone (control). Stable cell lines were isolated, cell lysates were pre
(loading control). B: Transwell migration assay of control and Fn14-overexpre
cells. For migration and invasion assays, the values shown are the mean 
0.01.number of gross lung tumors was 40% higher in miceFigure 8. Fn14 overexpression in NSCLC cells enhances experimental me-
tastases in vivo. A: H&E-stained lung sections from Beige mice with severe
combined immunodeficiency, injected i.v. with either control A549 or Fn14-
overexpressing A549 cells. Arrows indicate tumors. B: Average number of
experimental metastases in lung tumors from mice injected with control A549in vitro. A: A549 cells were infected with lentivirus expressing full-length hFn14-HA
pared, and immunoblotting was conducted using antibodies against HA and tubulin
ssing A549 cells. C:Matrigel invasion assay of control and Fn14-overexpressing A549or Fn14-overexpressing A549 cells (n  9 per group). The values shown are
the mean SEM. Significance was assessed by the Student’s t-test. *P 0.05.
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control cells (Figure 8B).
Discussion
In this study, we demonstrate that Fn14 was highly ex-
pressed in human NSCLCs and correlates with the ex-
pression of phosphorylated EGFR. We also show that
activation of EGFR signaling, either through EGF:EGFR
binding or mutations in the EGFR kinase domain, en-
hance Fn14 protein expression, and that pharmacologi-
cal inhibition of EGFR signaling decreases Fn14 expres-
sion. In NSCLC cells harboring an EGFR-activating
mutation and the T790M EGFR mutation that reduces
EGFR TKI sensitivity, Fn14 levels are elevated and only
decrease after exposure to a high EGFR TKI dose. We
further demonstrate that Fn14 expression levels could
modulate NSCLC cell migration and invasion in vitro and
experimental lung metastasis in vivo.
The Fn14 protein is highly expressed in primary human
NSCLC tumors. This follows reports showing that Fn14
expression is enhanced in several human malignan-
cies,16,26 including glioblastoma,18,19 esophageal ade-
nocarcinoma,20,21 hepatocellular carcinoma,17 and
HER2 breast cancer.22,23 The ErbB family (ErbB1/
EGFR, ErbB2/HER2, ErbB3, and ErbB4) of transmem-
brane proteins, especially EGFR, has been firmly estab-
lished as important drivers and therapeutic targets in
solid tumors.31–33 Overexpression of EGFR and ErbB2 is
observed in NSCLC and confers poor prognosis and
chemoresistance.34 EGFR activation is achieved through
ligand binding, receptor overexpression, or receptor mu-
tation. EGF and many other growth factors and cytokines,
including fibroblast growth factors 1 and 2, platelet-de-
rived growth factor-BB, transforming growth factor-1,
and TWEAK, can induce Fn14 gene expression.16,19,27
Thus, we determined whether Fn14 was preferentially
overexpressed in NSCLC primary tumors with activated
EGFR. In both adenocarcinoma and squamous cell car-
cinoma subtypes, Fn14 expression was significantly cor-
related with tyrosine phosphorylated EGFR, a marker of
EGFR activation. Fn14 is also highly expressed in HER2
breast tumors.22 The observed association between Fn14
expression and ErbB family member activation suggests
that therapeutic targeting of Fn14 in tumors driven by on-
cogenic ErbB family members could benefit patients.
Along with receptor overexpression and EGF:EGFR
engagement, activation of EGFR can occur via mutations
in the EGFR kinase domain. EGFR-TK mutations occur in
10% to 15% of patients with NSCLC in the Western hemi-
sphere and in 30% to 50% of patients of Asian ethnic-
ity.6,7 In this study, we demonstrate that NSCLC cell lines
harboring EGFRs with activating mutations have in-
creased Fn14 expression. We further show that express-
ing EGFRs with TK domain mutations in immortalized rat
lung epithelial cells increased Fn14 expression. We
found that erlotinib exposure inhibited p-EGFR levels in
three NSCLC cell lines harboring EGFR-activating muta-
tions, with a concomitant reduction in Fn14. Although
patients with activating EGFR mutations initially respondto EGFR-TKIs, subsequent resistance and relapse are
common. Mechanisms of resistance include secondary
mutations in EGFR10,35 and amplification of other growth
factor receptors, such as c-Met.11–13 We also showed
that H1975 NSCLC cells harboring an activating EGFR
mutation and the T790M EGFR mutation, which reduces
sensitivity to EGFR-TKIs, sustain Fn14 protein expression
after exposure to erlotinib, except at high erlotinib con-
centrations. Thus, targeting of Fn14 may be an attractive
approach to treat patients with NSCLC who are resistant
to EGFR-TKI therapy.
EGF, through binding and activation of EGFR, is a
well-characterized inducer of cell migration and is fre-
quently used to stimulate lung cancer cell migration
in vitro.36–38 Herein, we showed that Fn14 depletion
through RNA interference reduced NSCLC cell migration
and invasion driven by EGF:EGFR binding or by activat-
ing mutations in EGFR. The suppression of Fn14 does not
completely abrogate EGF-induced lung cell migration or
invasion, indicating that other motility mechanisms are
still active in these cells. We also demonstrated that over-
expression of Fn14 enhanced NSCLC cell migration and
invasion in vitro and enhanced experimental lung metas-
tasis in vivo. Thus, our data suggest that Fn14 levels can
modulate NSCLC cell migration and invasion. This sup-
ports growing evidence that Fn14 is involved in control of
motility and the invasive properties of cancer cells. For
example, Watts and colleagues20 reported that modula-
tion of Fn14 expression affected the invasiveness of
esophageal adenocarcinoma cell lines. Also, overex-
pression of Fn14 induced an invasive phenotype in pros-
tate cancer cell lines.39 In breast cancer cell lines, the
ectopic expression of Fn14 enhanced invasion, whereas
suppression of Fn14 through RNAi reduced breast can-
cer cell invasion.22 Our laboratory has previously dem-
onstrated that Fn14 is expressed at high levels in invad-
ing glioma cells in vivo and that ectopic expression of
Fn14 stimulated glioma cell invasion and migration
through an Rac1-dependent mechanism in vitro.18,19 We
have also demonstrated that TWEAK, the ligand for Fn14,
stimulated matrix metalloproteinase 9 expression, a me-
diator of invasive activity, in glioma cells.40 Investigation
on the mechanism(s) by which Fn14 enhances invasive
phenotypes in NSCLC cells and other tumor cell lines is
ongoing.
Fn14 gene expression is often elevated in many di-
verse types of tumors compared with the corresponding
normal tissues,16,26 suggesting that Fn14 may be a ther-
apeutic target for cancer therapy. In fact, Zhou and col-
leagues41 described an Fn14 monoclonal antibody with
recombinant gelonin chemical conjugate, that sup-
pressed the growth of several cancer cell lines in vitro and
inhibited tumor growth in an in vivo model of bladder
cancer. In some cases, administration of anti-Fn14 mono-
clonal antibodies alone can inhibit tumor growth in xeno-
graft assays.26,42 Thus, tumor suppression through the
targeting of Fn14 may prove to be a therapeutic interven-
tion in NSCLC and other tumor types.
In conclusion, Fn14 is highly expressed in primary
human NSCLCs and correlated with activation of EGFR.
Consistent with this observation, most NSCLC cell lines
Fn14 Expression in NSCLC 119
AJP July 2012, Vol. 181, No. 1with activating EGFR mutations express high levels of
Fn14. Suppression of Fn14 reduced NSCLC migration
and invasion in vitro, whereas the overexpression of Fn14
enhanced migration and invasion in vitro and experimen-
tal metastasis in vivo. Thus, Fn14 may be a therapeutic
target for patients with NSCLC, in particular for those with
EGFR-driven tumors who have either primary or acquired
resistance to EGFR TKIs.
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